Mucin in Sputum of CF During Pulmonary Exacerbation

Cystic Fibrosis Clinical Trial

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00202072
• Other study ID #: 208/03
• Status: Unknown status
• Phase: N/A
• First received: September 12, 2005
• Last updated: September 12, 2005
• Start date: January 2004
• Est. completion date: September 2005

Study information

• Verified date: September 2005
• Source: Philipps University Marburg Medical Center
• Contact: Markus O Henke, MD
• Phone: 06421
• Email: markus.henke[@]staff.uni-marburg.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).

Description:

CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.

In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing.

The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease.

We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry. With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.

The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 25
• Est. completion date: September 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• cystic fibrosis

• chronic pseudomonas aeruginosa inflammation

• pulmonary exacerbation

Exclusion Criteria:

Related Conditions & MeSH terms

• Cystic Fibrosis

Locations

Country	Name	City	State
Germany	Pediatric department, CF center, University Giessen	Giessen
Germany	Pediatric department, CF center, University Marburg	Marburg

Sponsors (1)

Lead Sponsor	Collaborator
Philipps University Marburg Medical Center

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. Epub 2004 Feb 26. — View Citation